Sickle Cell Disease News Home | Sickle Cell Disease News
WEB5 days ago — Becoming educated and informed about sickle cell disease is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
Bluebird set for Lyfgenia’s launch after ‘remarkable’ approvals
WEBDec 21, 2023 — Bluebird Bio’s Lyfgenia (lovotibeglogene autotemcel) — formerly lovo-cel — was cleared for SCD patients, ages 12 and older, with a history of vaso-occlusive events …
Supporters gearing up to raise awareness for SCD in September
WEBAug 31, 2023 — Advocates, patients, caregivers, doctors and others impacted by sickle cell disease (SCD) are gathering in September to bring attention to the struggles and needs …
News Archives – Sickle Cell Disease News
WEBContract to boost Medicaid access to sickle cell treatment. The American Institutes for Research (AIR) has been awarded a $28 million federal contract to help make cell and gene therapy (CGT) treatments more accessible to Medicaid recipients, initially focusing on sickle cell disease (SCD).
Osivelotor for sickle cell disease | Sickle Cell Disease News
WEBMay 29, 2024 — Osivelotor, previously known as PF-07940367, GBT601, or GBT021601, is an investigational oral therapy being evaluated as a possible treatment for sickle cell disease (SCD). It’s being developed by Pfizer, which acquired osivelotor’s original developer, Global Blood Therapeutics, in a 2022 deal.
FDA approves lovo-cel, now Lyfgenia, for sickle cell disease
WEBDec 8, 2023 — The U.S. Food and Drug Administration (FDA) has approved lovotibeglogene autotemcel, a gene therapy from Bluebird Bio known as lovo-cel, for treating sickle cell …
FDA Approves 1st Sickle Cell Treatment, Oxbryta, Targeting Root...
WEBNov 26, 2019 — Oxbryta (voxelotor), a first sickle cell treatment that works to stop the sickling and destruction of red blood cells that mark this disease, has been given accelerated approval by the U.S. Food and Drug Administration (FDA) for patients ages 12 and older.
Oxbryta (voxelotor) – Sickle Cell Disease News
WEBMay 22, 2024 — What is Oxbryta for sickle cell disease? Oxbryta (voxelotor) is an oral therapy conditionally approved in the U.S. for children and adults with sickle cell disease …
About Us – Sickle Cell Disease News
WEBSickle Cell Disease News is a digital platform intended to provide the sickle cell disease (SCD) community with the most recent news and information on SCD, as well as first-hand community perspectives from our patient and caregiver columnists.
Vaso-Occlusive Crisis - Sickle Cell Disease News
WEBJan 4, 2022 — A vaso-occlusive crisis, or VOC, occurs when sickled red blood cells block blood flow to the point that tissues become deprived of oxygen. This in turn sets in motion an inflammatory response as the body tries to rectify the problem.
Skip to content